Form 4: Cytokinetics Director Wendell Wierenga Acquires Shares in Lieu of Cash Retainer
SEC Form 4
Director Wendell Wierenga acquired 114 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.
Summary
- On July 1, 2024, Wendell Wierenga, a director of Cytokinetics Inc., acquired 114 shares of common stock.
- The acquisition was a stock award in lieu of a cash retainer payment.
- Following the transaction, Wierenga directly owns 24,441 shares of Cytokinetics Inc. common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction (stock award in lieu of cash retainer) and doesn't indicate any major positive or negative developments for the company.
Positives
- The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Directors receiving stock in lieu of cash compensation is a fairly common practice, particularly in biotech companies, to conserve cash and align director incentives with shareholder value.
Stakeholder Impact
- The transaction could have a slightly positive impact on shareholders as it aligns the director's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Wendell Wierenga acquired 114 shares of Cytokinetics Inc. common stock. |
| 07/03/2024 | Date of signature: The Form 4 was signed on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.